Recently, the State Drug Administration approved the listing of porciolense injections declared by Beijing Yimiao Shenzhou Biomedical Co., Ltd. to treat adult patients with recurrent or refractory large B-cell lymphoma after second-line or above systemic treatment, including diffuse large B-cell lymphoma unspecified, grade 3b follicular lymphoma, and high-grade B-cell lymphoma. The marketing of this variety provides new treatment options for relevant patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.